Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 714 in Type II Refractory Celiac Disease
NCT02633020Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2016
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of ordesekimab in refractory celiac disease type II, sponsored by Amgen. Started Apr 2016; status: completed.
02
Drugs
ordesekimab
03
Conditions
refractory celiac disease type II
Beyond the preview
Go deeper on NCT02633020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633020.